252 related articles for article (PubMed ID: 17965776)
21. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
[TBL] [Abstract][Full Text] [Related]
22. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
25. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis.
Hu J; Wang H; Gu J; Liu X; Zhou X
Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1018-1027. PubMed ID: 30137199
[TBL] [Abstract][Full Text] [Related]
26. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Breitbach CJ; Burke J; Jonker D; Stephenson J; Haas AR; Chow LQ; Nieva J; Hwang TH; Moon A; Patt R; Pelusio A; Le Boeuf F; Burns J; Evgin L; De Silva N; Cvancic S; Robertson T; Je JE; Lee YS; Parato K; Diallo JS; Fenster A; Daneshmand M; Bell JC; Kirn DH
Nature; 2011 Aug; 477(7362):99-102. PubMed ID: 21886163
[TBL] [Abstract][Full Text] [Related]
27. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
[TBL] [Abstract][Full Text] [Related]
28. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.
Evgin L; Vähä-Koskela M; Rintoul J; Falls T; Le Boeuf F; Barrett JW; Bell JC; Stanford MM
Mol Ther; 2010 May; 18(5):896-902. PubMed ID: 20160706
[TBL] [Abstract][Full Text] [Related]
29. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
[TBL] [Abstract][Full Text] [Related]
30. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
33. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
34. [Development of the drug oncolytic immunotherapy based on vaccinia viruses (Vaccinia virus, Orthopoxvirus, Chordopoxvirinae, Poxviridae) against breast cancer.].
Bauer TV; Tregubchak TV; Maksyutov AZ; Kolosova IV; Maksyutov RA; Gavrilova EV
Vopr Virusol; 2020; 65(1):49-56. PubMed ID: 32496721
[TBL] [Abstract][Full Text] [Related]
35. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
[TBL] [Abstract][Full Text] [Related]
36. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
37. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
39. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
40. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.
Kuhn I; Harden P; Bauzon M; Chartier C; Nye J; Thorne S; Reid T; Ni S; Lieber A; Fisher K; Seymour L; Rubanyi GM; Harkins RN; Hermiston TW
PLoS One; 2008 Jun; 3(6):e2409. PubMed ID: 18560559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
